Want to join the conversation?
$MRK issued statement after conclusion of meeting of Endocrinologic and Metabolic Drugs Advisory Committee of FDA to discuss results of IMPROVE-IT, investigational study comparing treatment with VYTORIN (ezetimibe and simvastatin) to treatment with simvastatin alone in more than 18,000 patients presenting with acute coronary syndromes.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.